Page last updated: 2024-11-12
lr-90
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
LR-90: an advanced glycation endproduct inhibitor that prevents progression of diabetic nephropathy in streptozotocin-diabetic rats; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10212249 |
MeSH ID | M0465776 |
Synonyms (20)
Synonym |
---|
lr-90 |
CS-M0920 |
lr90 |
245075-84-7 |
2-[4-[[4-[[4-[[4-(2-carboxypropan-2-yloxy)phenyl]carbamoylamino]-3-chlorophenyl]methyl]-2-chlorophenyl]carbamoylamino]phenoxy]-2-methylpropanoic acid |
2,2'-(4,4'-(4,4'-methylenebis(2-chloro-4,1-phenylene))bis(azanediyl)bis(oxomethylene)bis(azanediyl)bis(4,1-phenylene))bis(oxy)bis(2-methylpropanoic acid) |
unii-pj8v885848 |
pj8v885848 , |
propanoic acid, 2,2'-(methylenebis((2-chloro-4,1-phenylene)iminocarbonylimino-4,1-phenyleneoxy))bis(2-methyl- |
2,2'-(methylenebis((2-chloro-4,1-phenylene)iminocarbonylimino-4,1-phenyleneoxy))bis(2-methylpropanoic acid) |
CS-13737 |
2,2'-((((((methylenebis(2-chloro-4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(azanediyl))bis(4,1-phenylene))bis(oxy))bis(2-methylpropanoic acid) |
EX-A3319 |
BCP33770 |
lr 90;lr90 |
HY-76383 |
2,2-[methylenebis[(2-chloro-4,1-phenylene)iminocarbonylimino-4,1-phenyleneoxy]]bis[2-methylpropanoic acid] |
AKOS037649828 |
2,2-[methylenebis[(2-chloro-4,1-phenylene)iminocarbonylimino-4,1-phenyleneoxy]]bis[2-methylpropanoicacid] |
AC-35655 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (50.00) | 29.6817 |
2010's | 5 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 33.84
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.84) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |